Successful Erlotinib Treatment for a Patient with Gefitinib-Related Hepatotoxicity and Lung Adenocarcinoma Refractory to Intermittently Administered Gefitinib
A 73-year-old Japanese man was histologically diagnosed with lung adenocarcinoma harboring an exon 19 deletion in the epidermal growth factor receptor. The patient was treated with gefitinib for 6 weeks until he developed substantially elevated hepatic enzyme levels that resulted in the discontinuat...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Case Reports in Pulmonology |
| Online Access: | http://dx.doi.org/10.1155/2011/812972 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832555498798317568 |
|---|---|
| author | Tatsuya Nagano Yoshikazu Kotani Kazuyuki Kobayashi Masahiro Katsurada Yukihisa Hatakeyama Suya Hori Daisuke Tamura Daisuke Kasai Yasuhiro Funada Yoshihiro Nishimura |
| author_facet | Tatsuya Nagano Yoshikazu Kotani Kazuyuki Kobayashi Masahiro Katsurada Yukihisa Hatakeyama Suya Hori Daisuke Tamura Daisuke Kasai Yasuhiro Funada Yoshihiro Nishimura |
| author_sort | Tatsuya Nagano |
| collection | DOAJ |
| description | A 73-year-old Japanese man was histologically diagnosed with lung adenocarcinoma harboring an exon 19 deletion in the epidermal growth factor receptor. The patient was treated with gefitinib for 6 weeks until he developed substantially elevated hepatic enzyme levels that resulted in the discontinuation of gefitinib. Gefitinib was reintroduced with an intermittent treatment schedule after the transaminase levels normalized, but the patient's enzyme levels rose again, and the cancer progressed. Gefitinib was eventually replaced with erlotinib. There was stable disease for 7 weeks without any signs of liver toxicity. Thus, erlotinib may be a beneficial and well-tolerated treatment option for patients with gefitinib-related hepatotoxicity. |
| format | Article |
| id | doaj-art-e2e44f58ec9842aaba4e8b2db846b2ff |
| institution | Kabale University |
| issn | 2090-6846 2090-6854 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Pulmonology |
| spelling | doaj-art-e2e44f58ec9842aaba4e8b2db846b2ff2025-02-03T05:48:13ZengWileyCase Reports in Pulmonology2090-68462090-68542011-01-01201110.1155/2011/812972812972Successful Erlotinib Treatment for a Patient with Gefitinib-Related Hepatotoxicity and Lung Adenocarcinoma Refractory to Intermittently Administered GefitinibTatsuya Nagano0Yoshikazu Kotani1Kazuyuki Kobayashi2Masahiro Katsurada3Yukihisa Hatakeyama4Suya Hori5Daisuke Tamura6Daisuke Kasai7Yasuhiro Funada8Yoshihiro Nishimura9Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunokicho, Chuo-ku, Kobe, Hyogo 650-0017, JapanDivision of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunokicho, Chuo-ku, Kobe, Hyogo 650-0017, JapanDivision of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunokicho, Chuo-ku, Kobe, Hyogo 650-0017, JapanDivision of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunokicho, Chuo-ku, Kobe, Hyogo 650-0017, JapanDivision of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunokicho, Chuo-ku, Kobe, Hyogo 650-0017, JapanDivision of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunokicho, Chuo-ku, Kobe, Hyogo 650-0017, JapanDivision of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunokicho, Chuo-ku, Kobe, Hyogo 650-0017, JapanDivision of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunokicho, Chuo-ku, Kobe, Hyogo 650-0017, JapanDivision of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunokicho, Chuo-ku, Kobe, Hyogo 650-0017, JapanDivision of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunokicho, Chuo-ku, Kobe, Hyogo 650-0017, JapanA 73-year-old Japanese man was histologically diagnosed with lung adenocarcinoma harboring an exon 19 deletion in the epidermal growth factor receptor. The patient was treated with gefitinib for 6 weeks until he developed substantially elevated hepatic enzyme levels that resulted in the discontinuation of gefitinib. Gefitinib was reintroduced with an intermittent treatment schedule after the transaminase levels normalized, but the patient's enzyme levels rose again, and the cancer progressed. Gefitinib was eventually replaced with erlotinib. There was stable disease for 7 weeks without any signs of liver toxicity. Thus, erlotinib may be a beneficial and well-tolerated treatment option for patients with gefitinib-related hepatotoxicity.http://dx.doi.org/10.1155/2011/812972 |
| spellingShingle | Tatsuya Nagano Yoshikazu Kotani Kazuyuki Kobayashi Masahiro Katsurada Yukihisa Hatakeyama Suya Hori Daisuke Tamura Daisuke Kasai Yasuhiro Funada Yoshihiro Nishimura Successful Erlotinib Treatment for a Patient with Gefitinib-Related Hepatotoxicity and Lung Adenocarcinoma Refractory to Intermittently Administered Gefitinib Case Reports in Pulmonology |
| title | Successful Erlotinib Treatment for a Patient with Gefitinib-Related Hepatotoxicity and Lung Adenocarcinoma Refractory to Intermittently Administered Gefitinib |
| title_full | Successful Erlotinib Treatment for a Patient with Gefitinib-Related Hepatotoxicity and Lung Adenocarcinoma Refractory to Intermittently Administered Gefitinib |
| title_fullStr | Successful Erlotinib Treatment for a Patient with Gefitinib-Related Hepatotoxicity and Lung Adenocarcinoma Refractory to Intermittently Administered Gefitinib |
| title_full_unstemmed | Successful Erlotinib Treatment for a Patient with Gefitinib-Related Hepatotoxicity and Lung Adenocarcinoma Refractory to Intermittently Administered Gefitinib |
| title_short | Successful Erlotinib Treatment for a Patient with Gefitinib-Related Hepatotoxicity and Lung Adenocarcinoma Refractory to Intermittently Administered Gefitinib |
| title_sort | successful erlotinib treatment for a patient with gefitinib related hepatotoxicity and lung adenocarcinoma refractory to intermittently administered gefitinib |
| url | http://dx.doi.org/10.1155/2011/812972 |
| work_keys_str_mv | AT tatsuyanagano successfulerlotinibtreatmentforapatientwithgefitinibrelatedhepatotoxicityandlungadenocarcinomarefractorytointermittentlyadministeredgefitinib AT yoshikazukotani successfulerlotinibtreatmentforapatientwithgefitinibrelatedhepatotoxicityandlungadenocarcinomarefractorytointermittentlyadministeredgefitinib AT kazuyukikobayashi successfulerlotinibtreatmentforapatientwithgefitinibrelatedhepatotoxicityandlungadenocarcinomarefractorytointermittentlyadministeredgefitinib AT masahirokatsurada successfulerlotinibtreatmentforapatientwithgefitinibrelatedhepatotoxicityandlungadenocarcinomarefractorytointermittentlyadministeredgefitinib AT yukihisahatakeyama successfulerlotinibtreatmentforapatientwithgefitinibrelatedhepatotoxicityandlungadenocarcinomarefractorytointermittentlyadministeredgefitinib AT suyahori successfulerlotinibtreatmentforapatientwithgefitinibrelatedhepatotoxicityandlungadenocarcinomarefractorytointermittentlyadministeredgefitinib AT daisuketamura successfulerlotinibtreatmentforapatientwithgefitinibrelatedhepatotoxicityandlungadenocarcinomarefractorytointermittentlyadministeredgefitinib AT daisukekasai successfulerlotinibtreatmentforapatientwithgefitinibrelatedhepatotoxicityandlungadenocarcinomarefractorytointermittentlyadministeredgefitinib AT yasuhirofunada successfulerlotinibtreatmentforapatientwithgefitinibrelatedhepatotoxicityandlungadenocarcinomarefractorytointermittentlyadministeredgefitinib AT yoshihironishimura successfulerlotinibtreatmentforapatientwithgefitinibrelatedhepatotoxicityandlungadenocarcinomarefractorytointermittentlyadministeredgefitinib |